Item 8.01 Other Events.

On December 8, 2020, Syros Pharmaceuticals, Inc., a Delaware corporation (the "Company"), issued a press release announcing the closing of a previously announced private placement of an aggregate of 10,312,500 shares of the Company's common stock, par value $0.001 per share (the "Shares"), and, in lieu of Shares, pre-funded warrants (the "Pre-Funded Warrants") to purchase an aggregate of 1,000,000 shares of common stock, and, in each case, accompanying warrants (the "Warrants") to purchase an aggregate of up to 2,828,125 additional shares of common stock (or Pre-Funded Warrants to purchase common stock in lieu thereof) at a price of $8.00 per share and accompanying Warrant (or $7.99 per Pre-Funded Warrant and accompanying Warrant). The private placement resulted in gross proceeds of approximately $90.5 million, before deducting estimated offering expenses payable by the Company. The full text of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.






Exhibit
  No.       Description

99.1          Press Release, dated December 8, 2020

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses